Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, 2-Period Sequential Drug Interaction Study To Evaluate The Effect Of A 100 Mg Dose Of Desvenlafaxine SR On The Pharmacokinetics Of Aripiprazole When Coadministered In Healthy Subjects

NCT01188668 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01188668
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01188668 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, 2-Period Sequential Drug Interaction Study To Evaluate The Effect Of A 100 Mg Dose Of Desvenlafaxine SR On The Pharmacokinetics Of Aripiprazole When Coadministered In Healthy Subjects
Lead sponsor
Pfizer
Phase
Phase 4
Overall status
Completed
Start date
August 31, 2010
Completion date
October 31, 2010
Enrollment
38 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

cyp3a4 protein, human, cytochrome p-450 cyp2d6, pharmacokinetics